



# Speaker Bios

Arisha Patel, MD, MBA · 25, 100, and 300 words

hello@arishapatelmd.com · arishapatelmd.com

## 25 WORDS

Arisha Patel, MD, MBA is a triple board-certified Oncologist, physician-scientist, and Founder and CEO of BioNurture and BioSynova, building precision oncology for prevention and survivorship.

## 100 WORDS

Arisha Patel, MD, MBA is a triple board-certified Oncologist, Hematologist, and Internist, an NIH-funded physician-scientist in machine learning, and a former Senior Medical Director of Personalized Healthcare at Genentech, where her basket trial work supported NCCN guideline recommendations. She served as Adjunct Clinical Instructor in Oncology and Hematology at Stanford. She is the Founder and CEO of BioNurture, a concierge oncology practice for prevention and survivorship, and BioSynova, the clinical intelligence company developing the Cancer Resilience Index. She has worked in the clinic, the research lab, the drug industry, and the academic center, and she is building what comes next.

## 300 WORDS

Arisha Patel, MD, MBA is a triple board-certified Oncologist, Hematologist, and Internist. An NIH T32-funded physician-scientist, she was one of the first physicians to apply machine learning in clinical outcomes research, building predictive models in sickle cell disease with a cross-disciplinary team spanning UPMC and Carnegie Mellon, published in the British Journal of Haematology. She earned her MBA at Carnegie Mellon's Tepper School of Business in Biomedical Entrepreneurship and AI in Healthcare alongside her medical training, then carried that fluency into precision oncology drug development as Senior Medical Director of Personalized Healthcare at Genentech, where she served as Medical Director for MyPathway, a tumor-agnostic basket trial whose data supported NCCN Category 2A guideline recommendations and opened access to targeted therapy for patients outside traditional approval pathways. She served as Adjunct Clinical Instructor in Oncology and Hematology at Stanford, practicing as a breast oncologist before broadening across tumor types and blood disorders.

She is the Founder and CEO of BioNurture, a concierge oncology and hematology practice for cancer prevention, elevated-risk care, and survivorship, and BioSynova, the clinical intelligence company behind it, which is developing the Cancer Resilience Index, a longitudinal measure of cancer risk now in research validation. Her thesis is simple and consequential: cancer is not an event. It is a process that begins years before diagnosis and continues for decades after treatment, and almost everything in oncology is built for the window in between.

Her work has appeared in The Lancet Oncology, Cancer Discovery, JCO Clinical Cancer Informatics, the British Journal of Haematology, and Cancer, and on the stages of ASCO, AACR, and ASH. She writes and hosts The Cancer Resilience Code. She speaks to medical, investor, technology, and general audiences on predictive cancer care, AI in medicine, survivorship, and what the dying teach the living.